## The Effect of Female Sex on Short-Term Outcomes of Patients Undergoing Off-Pump *Versus* On-Pump Coronary Artery Bypass Grafting

Jun Fan<sup>1#</sup>, MD, PhD; Shao-ling Luo<sup>1#</sup>, MD; Yi-chao Pan<sup>1#</sup>; Tian-yuan Wu<sup>1</sup>, MD; Yu Chen<sup>1</sup>, MD; Wei-jie Li<sup>1</sup>, PhD

DOI: 10.21470/1678-9741-2021-0301

#### ABSTRACT

Introduction: According to the American Heart Association guideline for coronary artery bypass grafting (CABG), female patients undergoing on-pump CABG (ONCAB) are at higher risk of short-term adverse outcomes than male patients. However, whether off-pump CABG (OPCAB) can improve the short-term outcome of female patients compared to ONCAB remains unclear. Methods: We conducted a meta-analysis to study the effect of the female sex on short-term outcomes of OPCAB vs. ONCAB. A total of 31,115 patients were enrolled in 12 studies, including 20,245 females who underwent ONCAB and 10,910 females who underwent OPCAB. Results: The in-hospital mortality in female patients who underwent OPCAB was significantly lower than in those in the ONCAB group with (2.7% vs. 3.4%; odds ratio [OR] 0.76; 95% confidence interval [CI] 0.65-0.89) and without (OR 0.68; 95% CI 0.52-0.89) adjustment

for cardiovascular risk factor. The incidence of postoperative stroke in female patients who underwent OPCAB was lower than in those in the ONCAB group (1.2% vs. 2.1%; OR 0.59; 95% CI 0.48-0.73) before cardiovascular risk factor adjustment but was not significant (OR 0.87; 95% CI 0,66-1.16) after adjustment. There was no significant difference in the incidence of postoperative myocardial infarction between women who underwent OPCAB and those in the ONCAB group (1.3% vs. 2.3%; OR 0.88; 95% CI 0.54-1.43).

Conclusion: In contrast to the American Heart Association CABG guideline, female patients who had OPCAB don't have unfavorable outcomes compared with the ONCAB group.

Keywords: Coronary Artery Bypass. Myocardial Infarction. Gender. Heart Disease Risk Factors. Treatment Outcome.

Abbreviatio	ns, Acronyms & Symbols		
AF	= Atrial fibrillation	LVEF	= Left ventricular ejection fraction
aOR	= Adjusted odds ratio	M-H	= Mantel-Haenszel
ARF	= Acute renal failure	МІ	= Myocardial infarction
CABG	= Coronary artery bypass grafting	ONCAB	= On-pump CABG
CAD	= Coronary artery disease	OPCAB	= Off-pump CABG
CI	= Confidence interval	OR	= Odds ratio
CNKI	= China National Knowledge Infrastructure	PSM	= Propensity score matching
CORONARY	= CABG Off or On Pump Revascularization Study	ROOBY	= Randomized On/Off Bypass trial
df	= Degree of freedom	SE	= Standard error
IV	= Inverse variance	SinoMed	= Chinese biomedical literature service system

<sup>1</sup>Department of Cardiology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, People's Republic of China.

\*Contributed equally.

Correspondence Address: Wei-jie Li The https://orcid.org/0000-0002-7103-7543 Department of Cardiology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology No. 1 Panfu Road, Guangzhou, People's Republic of China Zip Code: 510180 E-mail: eylwj@scut.edu.cn Article received on May 13<sup>th</sup>, 2021.

Article accepted on May 13<sup>th</sup>, 2021. Article accepted on January 7<sup>th</sup>, 2022.

This study was carried out at the Department of Cardiology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, People's Republic of China.

### INTRODUCTION

Coronary artery disease (CAD) is the leading cause of death in both developed and developing countries<sup>[1]</sup>. The mortality and quality of life of CAD patients have been significantly improved by the effective application of primary<sup>[2]</sup> and secondary prevention<sup>[3]</sup>. Clinical trials have shown that improving the management of hypertension<sup>[4]</sup>, diabetes mellitus<sup>[5]</sup>, and hyperlipidemia<sup>[6]</sup> promoted better clinical outcomes in CAD patients. However, several risks factors affecting the outcomes of CAD patients remain unclear<sup>[7]</sup>.

Coronary artery bypass grafting (CABG) is a treatment strategy for coronary artery revascularization. According to the American Heart Association CABG guideline, the female sex is a risk factor for adverse outcomes<sup>[8]</sup>. In Kim et al.<sup>[9]</sup> meta-analysis involving 23 studies, early mortality and complications were higher among females after CABG than among males. However, this conclusion was based on the studies of on-pump CABG (ONCAB) or studies not stratified based on the cardiopulmonary bypass technique used.

In the CABG Off or On Pump Revascularization Study<sup>[10]</sup> (CORONARY) and the Randomized On/Off Bypass trial<sup>[11]</sup> (ROOBY), there was no significant difference between off-pump CABG (OPCAB) and ONCAB in the 30-day mortality rate. In addition, there was no significant difference in the occurrence of myocardial infarction (MI), stroke, or renal failure requiring dialysis between OPCAB and ONCAB groups in the CORONARY study<sup>[10]</sup>. However, to this date, there are no reports concerning the influence of sex difference on the outcomes of OPCAB *vs*. ONCAB clinically.

The study by Attaran et al.<sup>[12]</sup> was the first meta-analysis that compared the short-term outcomes between off-pump vs. on-pump revascularization among female patients. In this study, no statistically significant difference was observed in the 30-day mortality rate and other morbidity outcomes between the OPCAB and ONCAB groups, except for perioperative MI. Recently, several new studies in this field, including the propensity score matching (PSM) study<sup>[13]</sup> and studies that were adjusted for cardiovascular risk factors<sup>[13,14]</sup>, have been published. This study aims to investigate the latest research to study the effect of the female sex on short-term outcomes in OPCAB vs. ONCAB patients.

### METHODS

Since this study is a systematic review and meta-analysis based on previous articles, ethics committee approval was not required; it was conducted in accordance with the Helsinki Declaration of 1975 (revised in the year 2000). This is an observational meta-analysis that followed the guidelines for the Meta-analysis of Observational Studies in Epidemiology. This study has been registered on PROSPERO (CRD42021250888). We searched literature databases including PubMed®, Web of Science™, Embase®, Scopus™, Ovid, the China National Knowledge Infrastructure (or CNKI), the Chinese Biomedical Literature service system (or SinoMed), and the Wanfang Data Knowledge Service Platform with the keywords "coronary artery bypass", "female", "women", "woman", "gender", and "sex". We did not limit the start time of the studies, but we limited their end time to 2021-8-1, when retrieving the literature. After this strategy, 4,358 pieces of literature were retrieved. LSL and PYC carefully read and analyzed all the retrieved studies, and the publications were further

screened according to the flow chart shown in Figure 1. Finally, 12 retrospective observational studies were included in our metaanalysis. Of the 12 studies, two were PSM studies.

We included two main types of studies in our meta-analysis: 1) studies which only included female patients grouped by OPCAB and ONCAB and 2) studies which included male and female patients undergoing CABG (OPCAB and ONCAB), but containing a clear delineation between OPCAB and ONCAB subgroups. Both types of studies must also possess documented primary and secondary endpoints.

Primary endpoints included in-hospital death, 30-day death rate after surgery, postoperative MI, and stroke. Secondary endpoints included postoperative acute renal failure (ARF), renal replacement therapy, blood transfusion, reoperation for bleeding, sternal wound infection, atrial fibrillation, and postoperative lower cardiac output.

The selected literature was not restricted by language. Abstracts, conference abstracts, and supplementary issues were also included. Patients who underwent concomitant surgical procedures such as valvular repair or replacement, correction of congenital malformation, and ascending aortic aneurysm repair, to name a few, were excluded from this study. FJ and PYC analyzed the data extracted from these studies. A consensus was reached through discussion in cases of disagreements.

### **Extraction of Data**

LWJ and FJ extracted data from the selected literature, including the first author's name, the year when the study was published, the type of research, and the country where the study was conducted. General characteristics such as age, race, body mass index, and smoking status were recorded. Preoperative diseases including hypertension, diabetes, hyperlipidemia, heart failure, stroke, and peripheral vascular disease were included. Patients' echocardiographic measurement parameters, such as left ventricular ejection fraction, were also collected. Primary and secondary endpoints were collected for investigation. The quality of the studies was evaluated according to the Newcastle-Ottawa Scale (or NOS).


### **Statistical Analysis**

RevMan 5.4 (Nordic Cochrane Center) statistical software was employed for meta-analysis. A *P*-value of < 0.05 was considered statistically significant. Publication bias was assessed using visual inspection of funnel plots. All included studies were retrospective in nature. A random-effects model was adopted in this study to avoid the impact of inter-study heterogeneity on the results.

### RESULTS

### Literature Retrieval

We searched the literature database as abovementioned; 4,358 scientific works were retrieved after preliminary screening. We then further screened the literature according to the strategy in Figure 1. Ultimately, 12 studies were included in our metaanalysis. All studies were retrospective observational studies. Primary and secondary endpoints were extracted for analysis.



**Fig. 1** - Flow diagram describing study selection in our meta-analysis. CABG=coronary artery bypass grafting; CNKI=China National Knowledge Infrastructure; SinoMed=Chinese biomedical literature service system

### **Characteristics of the Included Studies**

The 12 studies included were observational, three reports were from the United States of America<sup>[13,15-18]</sup>, and the remaining were clinical studies from Germany<sup>[19-21]</sup>, Netherlands<sup>[14,22]</sup>, Portugal<sup>[23]</sup>, Poland<sup>[24-27]</sup>, and Canada<sup>[28,29]</sup>. The detailed characteristics of the included patients and quality assessment are shown in Table 1. We investigated in-hospital mortality rate (Figure 2), 30-day hospital mortality rate (Figure 3), myocardial

infarction incidence (Figure 4), stroke incidence (Figure 5), incidence of red blood cell transfusion and re-exploration for bleeding (Supplementary Figure 1), acute renal failure and renal replacement therapy (Supplementary Figure 2), deep wound infection (Supplementary Figure 3A), atrial fibrillation (Supplementary Figure 3B), and postoperative lower cardiac output (Supplementary Figure 3C) among female patients received ONCAB or OPCAB. A funnel plot is shown in Supplementary Figures 4-8.

Source	Region	Design	Total of women, n°	OPCAB, nº	ONCAB, nº	Study quality*
Woorst	Netherlands	Observational	3,684	414	3,37	6
Rieß	Germany	Observational	660	259	401	4
Sá	Portugal	Observational	941	549	392	4
Eifert	Germany	Observational	733	252	481	7
Maganti	Canada	Observational	296	148	148	8
Czech	Poland	Observational	677	275	402	4
Bucerius	Canada	Observational	2,182	152	2,03	4
Mack	United States of America	Observational	7,376	3,688	3,688	4
Perek	Poland	Observational	301	31	270	4
Petro	United States of America	Observational	1,831	304	1,527	6
Puskas	United States of America	Observational	3248	1,381	1,867	6
Woś	Poland	Observational	689	31	658	4

#### **Table 1.** Characteristics of the included studies.

ONCAB=on-pump coronary artery bypass grafting; OPCAB=off-pump coronary artery bypass grafting \*Newcastle-Ottawa quality assessment scale for cohort studies

### **Clinical Characteristics of the Included Patients**

A total of 31,115 patients were enrolled in the 12 studies, including 20,245 women who underwent ONCAB and 10,910 women who underwent OPCAB. The clinical characteristics and differences between female patients who underwent OPCAB or ONCAB, including age, hypertension, diabetes, smoking status, ejection fraction, chronic obstructive pulmonary disease, peripheral vascular disease, and previous MI, are shown in Table 2.

### Effect of OPCAB on In-Hospital Mortality Rate Among Female Patients

We included eight studies to investigate the effect of OPCAB on in-hospital mortality in women. Female coronary heart disease patients undergoing ONCAB were the control group. A total of 23,896 women were enrolled in these eight studies, including 9,833 women who underwent OPCAB and 14,063 women who underwent ONCAB. The number of deaths in OPCAB and ONCAB patients was 264 and 483, respectively. The in-hospital mortality rate in female patients who underwent OPCAB was significantly lower than in those in the ONCAB group (2.7% vs. 3.4%; odds ratio [OR] 0.76; 95% confidence interval [CI] 0.65-0.89) (Figure 2A).

In two of the eight studies, OR values were corrected for cardiovascular risk factors. Consistently with the meta-analysis results of these eight studies, the mortality rate of female patients who underwent OPCAB was lower than of those in the ONCAB group (OR 0.68; 95% CI 0.52-0.89) (Figure 2B).

Among these eight studies, a PSM method was employed in two of them. A total of 3,836 female patients who underwent

OPCAB and 3,836 female patients who underwent ONCAB were enrolled in these two studies. The number of deaths in OPCAB and ONCAB patients was 118 and 146, respectively. In contrast to the abovementioned results, there was no significant difference in in-hospital mortality rate between female patients who underwent OPCAB or ONCAB (3.1% vs. 3.8%; OR 0.80; 95% CI 0.63-1.03) (Figure 2C).

### Effect of OPCAB on 30-Day Hospital Mortality Rate Among Female Patients

We selected four studies to investigate the effect of OPCAB on the 30-day postoperative mortality rate in female patients. Female patients who underwent ONCAB were employed as the control group. A total of 7,529 women were enrolled in these four studies, including 1,077 OPCAB patients and 6,182 ONCAB patients. The female 30-day death rate of OPCAB and ONCAB were nine and 222, respectively. Patients who underwent OPCAB had a lower 30-day mortality rate than those in the ONCAB group (0.8% *vs.* 3.6%; OR 0.28; 95% Cl 0.15-0.55) (Figure 3).

### Effect of OPCAB on Myocardial Infarction Incidence Among Female Patients

We included six studies to investigate the effect of OPCAB on postoperative MI in female patients. There was no significant difference in the incidence of postoperative MI in women who underwent OPCAB compared with those that underwent ONCAB (1.3% vs. 2.3%; OR 0.88; 95% CI 0.54-1.43). Of the 12 studies included in this study, the PSM method was employed in one, and the result of this study was consistent with previous results (Figure 4).

	Age, me	an, years	Diabe	tes, %	Hyperte	nsion, %	Dyslipid	lemia, %	Smok	ing, %	LVEF, %	
Source	OPCAB	ONCAB	OPCAB	ONCAB	ОРСАВ	ONCAB	OPCAB	ONCAB	OPCAB	ONCAB	OPCAB	ONCAB
Woorst	67.6 ª	68.8	24.4 ª	29.5	62.6	59.0	NR	NR	NR	NR	NR	NR
Rieß	71.6	70.4	28.2	30.2	NR	NR	NR	NR	25.1	24.7	NR	NR
Sá	68.6	69.2	45.9 ª	35.9	68.7 ª	72.1	NR	NR	14.2	12.7	NR	NR
Eifert	66.2	65.5	13.5	15	59.7	63.7	NR	NR	41.6	44.3	64.3	58.9
Maganti	65	64	41	41	70	68	74	73	NR	NR	NR	NR
Czech	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Bucerius	67.9	68.1	45.4	44.6	82.2	78.3	55.3	55.9	NR	NR	NR	NR
Mack	68.6	68.9	34.6	34.2	69.5 ª	66.6	NR	NR	13.7	12.6	NR	NR
Perek	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Petro	67	66	36 ª	46	NR	NR	NR	NR	NR	NR	NR	NR
Puskas	65.1	64.8	42	42	84	79	NR	NR	33	26	NR	NR
Woś	57	62	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR

Table 2. Characteristics of study participants from the included studies.

LVEF=left ventricular ejection fraction; NR=not reported; ONCAB=on-pump coronary artery bypass grafting; OPCAB=off-pump coronary artery bypass grafting

<sup>a</sup>Indicates a statistically significant association

# Effect of OPCAB on Stroke Incidence Among Female Patients

We included eight studies to investigate the effect of OPCAB on stroke in female patients. Female patients who underwent ONCAB were used as the control group. A total of 27,657 women were enrolled in these eight studies, including 10,269 women who underwent OPCAB and 17,388 women who underwent ONCAB. The number of postoperative strokes in OPCAB and ONCAB female patients was 123 and 359, respectively. The incidence of postoperative stroke in OPCAB female patients was lower than in those in the ONCAB group (1.2% vs. 2.1%; OR 0.59; 95% CI 0.48 - 0.73) (Figure 5A).

Among these eight studies, two used the PSM method. Consistently with previous results, the incidence of stroke in the OPCAB group was lower than in the ONCAB group (1.0% vs. 1.8%; OR 0.56; 95% CI 0.37-0.83) (Figure 5B). In two of the eight studies, postoperative stroke OR values were adjusted for cardiovascular risk factors. In contrast to previous results, there was no significant difference in the incidence of postoperative stroke between the OPCAB and ONCAB groups (OR 0.87; 95% CI 0.66-1.16) (Figure 5C).

### Effect of OPCAB on the Incidence of Red Blood Cell Transfusion and Re-exploration for Bleeding

We included three studies to investigate the effect of OPCAB on blood transfusion occurrence in female patients. The incidence of blood transfusion in female patients who received OPCAB was lower than in those in the ONCAB group (31.1% vs. 61.4%; OR 0.27; 95% CI 0.16-0.46) (Supplementary Figure 1A).

Seven studies were included to investigate the effect of OPCAB on re-exploration for bleeding among female patients. Postoperative re-exploration bleeding was lower in female OPCAB patients than in those in the ONCAB group (4.2% vs. 4.8%; OR 0.70; 95% CI 0.50-0.97) (Supplementary Figure 1B). However, in the meta-analysis of PSM studies, there was no significant difference in re-exploration for bleeding incidence in female ONCAB patients compared with the control group (Supplementary Figure 1C).

# Effect of OPCAB on Acute Renal Failure and Renal Replacement Therapy in Female Patients

We included seven studies to investigate the effect of OPCAB on postoperative ARF among female patients. A total of 25,508 women were enrolled, including 10,011 women who underwent OPCAB and 15,497 women who underwent ONCAB. The incidence of ARF in OPCAB female patients was lower than in those in the ONCAB group (1.9% vs. 3.6%; OR 0.62; 95% CI 0.42-0.91) (Supplementary Figure 2A). Two studies that investigated OR adjusted by cardiovascular risk factors also showed a lower risk of postoperative ARF in women who underwent OPCAB (OR 0.69; 95% CI 0.56-0.84) (Supplementary Figure 2B). We also found that the incidence of female patients receiving renal replacement therapy after surgery was lower in the OPCAB than in the ONCAB group (1.02% vs. 2.57%; OR 0.51; 95% CI 0.28-0.91) (Supplementary Figure 2C).

### (a)

	OPCA	В	ONC	AB		Odds Ratio		Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C		M-H, Random, 95% CI	
Czech 2007	6	275	18	402	2.8%	0.48 [0.19, 1.21]			
Mack 2015	117	3688	143	3688	39.7%	0.81 [0.63, 1.04]		-=	
Maganti 2007	1	148	3	148	0.5%	0.33 [0.03, 3.20]			
Perek 2003	0	31	17	270	0.3%	0.23 [0.01, 3.92]		· · ·	
Petro 2000	7	304	62	1527	3.9%	0.56 [0.25, 1.23]			
Puskas 2007	115	4807	212	6978	46.5%	0.78 [0.62, 0.98]			
Sa 2010	17	549	21	392	5.8%	0.56 [0.29, 1.08]			
Woś S 2001	1	31	7	658	0.5%	3.10 [0.37, 26.01]			_
Total (95% CI)		9833		14063	100.0%	0.76 [0.65, 0.89]		◆	
Total events	264		483						
Heterogeneity: Tau <sup>2</sup> =	0.00; Chi <sup>2</sup>	= 5.58	df = 7 (F	P = 0.59)	; l² = 0%		0.01	0.1 1 10	100
Test for overall effect: 2	Z = 3.46 (	P = 0.0	005)				0.01	Favours OPCAB Favours ONC	

### (b)

			Odds Ratio		Odds I	Ratio	
Study or Subgroup	log[Odds Ratio] SE	Weight	IV, Random, 95% CI		IV, Randor	<u>m, 95% Cl</u>	
Mack 2015	-0.5499 0.1779	40.1%	0.58 [0.41, 0.82]				
Puskas 2007	-0.2744 0.1292	59.9%	0.76 [0.59, 0.98]				
Total (95% CI)		100.0%	0.68 [0.52, 0.89]		$\bullet$		
Heterogeneity: Tau <sup>2</sup> =	0.01; Chi <sup>2</sup> = 1.57, df = 1 (P =	= 0.21); l <sup>2</sup>	= 36%			10	100
Test for overall effect:	Z = 2.85 (P = 0.004)			0.01	0.1 1	10	100
	,				Favours OPCAB	Favours ONCAB	

### (c)

	Experim	ental	Contr	ol		Odds Ratio		Odd	s Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		M-H, Ran	dom, 95% Cl	
Mack 2015	117	3688	143	3688	98.8%	0.81 [0.63, 1.04]				
Maganti 2007	1	148	3	148	1.2%	0.33 [0.03, 3.20]		· · · ·		
Total (95% CI)		3836		3836	100.0%	0.80 [0.63, 1.03]		•		
Total events	118		146							
Heterogeneity: Tau <sup>2</sup> =	0.00; Chi <sup>2</sup>	= 0.60, o	df = 1 (P =	= 0.44);	$ ^2 = 0\%$		0.01	01		100
Test for overall effect:	Z = 1.73 (F	9 = 0.08)					0.01	0.1 Favours OPCAB	1 10 Favours ONCAB	100

**Fig. 2** - Forest plots demonstrating in-hospital mortality of off-pump coronary artery bypass grafting (OPCAB) vs. on-pump coronary artery bypass grafting (ONCAB) for (a) original data without adjustment, (b) in-hospital mortality with cardiovascular risk factor adjustment, (c) in-hospital mortality of propensity score matching studies. Chi=Chi-squared; Cl=confidence interval; df=degree of freedom; IV=inverse variance; M-H=Mantel-Haenszel; SE=standard error; Tau=Tau-squared

## Effect of OPCAB on Deep Wound Infection in Female Patients

Six studies were included to investigate the impact of OPCAB on deep wound infection among female patients. A total of 9,707 OPCAB female patients and 13,970 ONCAB female patients were included in these studies. We found that the incidence of deep wound infection in OPCAB patients was lower than in ONCAB patients (0.3% vs. 0.7%; OR 0.58; 95% CI 0.37-0.90) (Supplementary Figure 3A).

## Effect of OPCAB on Atrial Fibrillation and Postoperative Lower Cardiac Output

We included six studies to investigate the effect of OPCAB on postoperative atrial fibrillation in women. A total of 6,319 female

	OPCA	В	ONC	AB		Odds Ratio		Odds	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl		M-H, Rando	om, 95% Cl	
Bucerius 2005	1	152	111	2030	11.5%	0.11 [0.02, 0.83]				
Eifert 2010	4	252	25	481	39.3%	0.29 [0.10, 0.85]				
Rieß 2017	0	259	6	401	5.4%	0.12 [0.01, 2.09]	←			
Woorst 2019	4	414	80	3270	43.9%	0.39 [0.14, 1.07]				
Total (95% CI)		1077		6182	100.0%	0.28 [0.15, 0.55]		-		
Total events	9		222							
Heterogeneity: Tau <sup>2</sup> =	0.00; Chi <sup>2</sup>	= 1.63	, df = 3 (F	P = 0.65	5); l <sup>2</sup> = 0%				10	400
Test for overall effect:	Z = 3.69 (	P = 0.0	002)				0.01	0.1 1 Favours OPCAB	10 Favours ONCAB	100

**Fig. 3** - Forest plot demonstrating the 30-day hospital mortality rate of off-pump coronary artery bypass grafting (OPCAB) vs. on-pump coronary artery bypass grafting (ONCAB). Chi=Chi-squared; CI=confidence interval; df=degree of freedom; M-H=Mantel-Haenszel; Tau=Tau-squared

	OPCA	В	ONC	AB		Odds Ratio		Odds	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C		M-H, Rando	om, 95% Cl	
Bucerius 2005	3	152	75	2030	12.9%	0.52 [0.16, 1.68]				
Eifert 2010	1	252	2	401	3.8%	0.79 [0.07, 8.81]				
Maganti 2007	6	148	2	148	7.6%	3.08 [0.61, 15.54]		_		
Puskas 2007	54	4807	124	6978	41.0%	0.63 [0.46, 0.87]				
Rieß 2017	1	259	2	401	3.8%	0.77 [0.07, 8.57]				
Woorst 2019	16	414	98	3270	31.0%	1.30 [0.76, 2.23]		+	-	
Total (95% CI)		6032		13228	100.0%	0.88 [0.54, 1.43]		-		
Total events	81		303							
Heterogeneity: Tau <sup>2</sup> =	0.12; Chi <sup>2</sup>	= 8.44	, df = 5 (F	P = 0.13)	; l <sup>2</sup> = 41%		0.01	0.1 1		100
Test for overall effect:	Z = 0.50 (	P = 0.6	2)				0.01	Favours OPACB		100

**Fig. 4** - Forest plot demonstrating postoperative myocardial infarction incidence of off-pump coronary artery bypass grafting (OPCAB) vs. on-pump coronary artery bypass grafting (ONCAB). Chi=Chi-squared; CI=confidence interval; df=degree of freedom; M-H=Mantel-Haenszel; Tau=Tau-squared

patients who underwent OPCAB and 9,927 female patients who underwent ONCAB were included in these studies. The incidence of postoperative atrial fibrillation showed no statistical difference in OPCAB patients compared with ONCAB patients (20.2% vs. 23.4%; OR 0.85; 95% CI 0.68-1.06) (Supplementary Figure 3B). Three studies were included to investigate the effect of OPCAB on postoperative lower cardiac output in women. The results showed no significant difference in postoperative lower cardiac output incidence in OPCAB patients compared with ONCAB patients (5.3% vs. 6.5%; OR 0.88; 95% CI 0.52-1.51) (Supplementary Figure 3C).

### DISCUSSION

In this study, we included 12 retrospective observational studies regarding the influence of the female sex on the short-term clinical outcomes following OPCAB and ONCAB. A total of 31,115 patients were included, which consisted of 20,245 males and 10,910 females. We observed that the incidence of adverse events in female patients who underwent OPCAB

was lower or not significant, but not higher, than in those in the ONCAB group.

According to the American Heart Association guidelines for CABG, women are at a higher risk for adverse clinical outcomes, including postoperative mortality and stroke<sup>[8]</sup>. However, most of these studies are based on ONCAB. Previous research from Risum et al.<sup>[29]</sup> confirmed that the risk of early mortality and low-output syndrome needing intra-aortic balloon support was higher in women than in men. In addition, a meta-analysis from Wognsen et al.<sup>[30]</sup> found that females run an increased risk of early death and the development of postoperative complications after CABG compared with males. These results were mainly caused by the increased complexity of the procedure due to women's smaller body surface area<sup>[30]</sup>.

OPCAB is performed on a beating heart without extracorporeal bypass compared with traditional extracorporeal bypass surgery. OPCAB has many advantages, such as shorter operation time, reduced hospitalization and intensive care

### (a)

	OPC/	AB	ONC	AB		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	<u>M-H, Random, 95% CI</u>
Bucerius 2005	2	152	69	2030	2.3%	0.38 [0.09, 1.56]	
Eifert 2010	2	252	19	481	2.2%	0.19 [0.04, 0.84]	
Mack 2015	38	3688	66	3688	28.7%	0.57 [0.38, 0.85]	
Maganti 2007	0	148	3	148	0.5%	0.14 [0.01, 2.73]	· · · ·
Puskas 2007	69	4807	147	6978	55.8%	0.68 [0.51, 0.90]	
Rieß 2017	2	259	3	401	1.4%	1.03 [0.17, 6.22]	
Sa 2010	7	549	16	392	5.8%	0.30 [0.12, 0.74]	
Woorst 2019	3	414	36	3270	3.3%	0.66 [0.20, 2.14]	
Total (95% CI)		10269		17388	100.0%	0.59 [0.48, 0.73]	•
Total events	123		359				
Heterogeneity: Tau <sup>2</sup> =	0.00; Chi <sup>2</sup>	= 6.93,	df = 7 (P	= 0.44);	$ ^2 = 0\%$		
Test for overall effect:	Z = 4.81 (F	<b>&gt;</b> < 0.00	001)				0.01 0.1 1 10 100 Favours OPCAB Favours ONCAB
(b)							

Study or Subgroup	log[Odds Ratio]	SF	Weight	Odds Ratio IV. Random, 95% Cl	I	IV.	Odds Ratio Random, 95		
Mack 2015	0.001	0.146	52.2%	1.00 [0.75, 1.33]		,	-	/• ••	
Puskas 2007	-0.2877	0.1582	47.8%	0.75 [0.55, 1.02]					
Total (95% CI)			100.0%	0.87 [0.66, 1.16]			•		
Heterogeneity: Tau <sup>2</sup> = Test for overall effect:			= 0.18); l²	= 44%	0.01 Favo	0.1 0urs [experim	1 ental] Favo	10 urs [control]	100

### (C)

	OPC/	B	ONCA	AΒ		Odds Ratio		Odds	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		M-H, Ranc	lom, 95% Cl	
Mack 2015	38	3688	66	3688	98.2%	0.57 [0.38, 0.85]				
Maganti 2007	0	148	3	148	1.8%	0.14 [0.01, 2.73]	•	•		
Total (95% CI)		3836		3836	100.0%	0.56 [0.37, 0.83]		•		
Total events	38		69							
Heterogeneity: Tau <sup>2</sup> =				9 = 0.36	5); I <sup>2</sup> = 0%		⊢ 0.01	0.1	1 10	100
Test for overall effect: 2	2 = 2.88 (	P = 0.0	04)					Favours OPCAB	Favours ONC	AB

**Fig. 5** - Forest plots demonstrating postoperative stroke incidence of off-pump coronary artery bypass grafting (OPCAB) vs. on-pump coronary artery bypass grafting (OPCAB) for (a) original data without adjustment, (b) stroke with cardiovascular risk factor adjustment, (c) stroke of propensity score matching studies. Chi=Chi-squared; Cl=confidence interval; df=degree of freedom; IV=inverse variance; M-H=Maentel-Haenszel; SE=standard error; Tau=Tau-squared

unit length of stay, lower medical costs, and fewer surgery-related complications<sup>[31]</sup>.

Large randomized controlled clinical trials, including CORONARY<sup>[10]</sup> and ROOBY<sup>[11]</sup>, found no significant difference between OPCAB and ONCAB regarding the 30-day death rate, MI, stroke, or renal failure requiring dialysis. However, these clinical studies did not investigate whether female patients who underwent OPCAB had a better short-term outcome compared to female patients who underwent ONCAB.

A meta-analysis from Attaran et al.<sup>[12]</sup> investigated shortterm outcomes among OPCAB *vs.* ONCAB female patients. In this study, no statistically significant difference was observed in the 30-day mortality rate and other morbidity outcomes between the OPCAB and ONCAB groups, except for perioperative MI. This study's results are limited because both 30-day mortality and not in-hospital mortality rates were considered primary endpoints after CABG, but most of the included research investigated in-hospital mortality rates. Although 30-day mortality and in-hospital mortality rates are both short-term effects, failure to delineate them may give incorrect conclusions. Furthermore, Attaran et al.'s study did not investigate the OR adjusted by cardiovascular risk factors, leading to confounding factors affecting the results<sup>[12]</sup>. In contrast to Attaran's study, we found that the in-hospital

### (a) Blood cell transfusion

	OPCA	B	ONC/	٨B		Odds Ratio		0	dds Ratio	)	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		M-H, R	andom, 9	5% CI	
Petro 2000	121	304	900	1527	33.4%	0.46 [0.36, 0.59]		-			
Sa 2010	168	549	269	392	32.8%	0.20 [0.15, 0.27]		-			
Woorst 2019	105	414	2015	3270	33.8%	0.21 [0.17, 0.27]		-			
Total (95% CI)		1267		5189	100.0%	0.27 [0.16, 0.46]		-			
Total events	394		3184								
Heterogeneity: Tau <sup>2</sup> =	0.20; Chi <sup>2</sup>	= 25.7	6, df = 2 (	(P < 0.0)	00001); l <sup>2</sup> :	= 92%				10	100
Test for overall effect:	Z = 4.88 (	P < 0.0	0001)				0.01	0.1 Favours OPC	AB Favo	10 ours ONCAE	100

### (b) Re-exploration for bleeding

	OPCA	AB	ONC	AB		Odds Ratio		Od	ds Rati	0	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H. Random, 95% Cl		M-H. Ra	ndom.	95% CI	
Bucerius 2005	10	152	138	2030	16.9%	0.97 [0.50, 1.88]			-		
Eifert 2010	10	252	43	481	15.5%	0.42 [0.21, 0.85]			-		
Maganti 2007	4	148	1	148	2.2%	4.08 [0.45, 36.97]		11			_
Petro 2000	4	304	33	1527	8.4%	0.60 [0.21, 1.72]		8	1		
Puskas 2007	234	4807	430	6978	47.0%	0.78 [0.66, 0.92]					
Rieß 2017	0	259	8	401	1.3%	0.09 [0.01, 1.55]	+		-		
Woorst 2019	4	414	60	3270	8.8%	0.52 [0.19, 1.44]			-		
Total (95% CI)		6336		14835	100.0%	0.70 [0.50, 0.97]		•			
Total events	266		713								
Heterogeneity: Tau <sup>2</sup> =	0.05; Chi <sup>2</sup>	= 8.42	, df = 6 (F	P = 0.21)	; l² = 29%					10	100
Test for overall effect:	Z = 2.12 (	P = 0.0	3)				0.01	0.1 Favours OPCA	B Fav	10 ours ONCAB	100

## (c) Re-exploration for bleeding PSM

	OPC	OPCAB ONCAB				Odds Ratio		Odds Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H. Random, 95% C		M-H. I	Random, 95%	6 CI	
Mack 2015	117	3688	143	3688	73.9%	0.81 [0.63, 1.04]					
Maganti 2007	4	148	1	148	26.1%	4.08 [0.45, 36.97]					
Total (95% CI)		3836		3836	100.0%	1.24 [0.31, 4.98]		-		-	
Total events	121		144								
Heterogeneity: Tau <sup>2</sup> =	0.67; Chi	<sup>2</sup> = 2.04	, df = 1 (F	P = 0.15	5); l <sup>2</sup> = 51%	6	0.04			10	100
Test for overall effect:							0.01 Favo	0.1 Jurs [experiment	i ntali Eavour	10 Ficontrol1	100

**Supplementary Fig. 1** - Forest plots demonstrating off-pump coronary artery bypass grafting (OPCAB) vs. on-pump coronary artery bypass grafting (ONCAB) incidence of (a) blood cell transfusion, (b) re-exploration for bleeding, (c) re-exploration for bleeding of propensity score matching (PSM) studies. Chi=Chi-squared; Cl=confidence interval; df=degree of freedom; M-H=Mantel-Haenszel; Tau=Tau-squared

and 30-day mortality rates in female patients who underwent OPCAB were significantly lower than in those in the ONCAB group in studies with and without cardiovascular risk factor adjustment. The in-hospital mortality rate of OPCAB female patients was not significantly different from ONCAB female patients in PSM studies. In the primary meta-analysis, the incidence of postoperative stroke in female patients who underwent OPCAB was lower than in those in the ONCAB group, while the difference in postoperative stroke between OPCAB and ONCAB in PSM studies and post-MI was insignificant. The incidence of unfavorable outcomes in female patients who underwent OPCAB was not higher than in those in the ONCAB group. In summary, the shortterm clinical outcomes of women who underwent OPCAB were not worse than of those in the ONCAB group. Notably, the in-hospital mortality and postoperative 30-day mortality rates of OPCAB patients were lower than of ONCAB patients. We surmise that this may be related to the fact that OPCAB causes less trauma and minimally affects patients' circulation compared to ONCAB.

Favours OPCAB Favours ONCAB

### (a) Acute Renal Failure

	OPCA	AB	ONC	AB		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H. Random, 95% CI	M-H. Random. 95% CI
Bucerius 2005	4	152	163	2030	10.2%	0.31 [0.11, 0.85]	
Eifert 2010	5	252	9	481	9.0%	1.06 [0.35, 3.20]	100 100 100 100 100 100 100 100 100 100
Mack 2015	31	3688	29	3688	21.2%	1.07 [0.64, 1.78]	
Petro 2000	1	304	7	1527	3.1%	0.72 [0.09, 5.85]	
Puskas 2007	136	4807	317	6978	30.7%	0.61 [0.50, 0.75]	
Rieß 2017	6	259	11	401	10.2%	0.84 [0.31, 2.30]	
Sa 2010	11	549	27	392	15.6%	0.28 [0.14, 0.56]	
Fotal (95% CI)		10011		15497	100.0%	0.62 [0.42, 0.91]	•
otal events	194		563				200.0
Heterogeneify: Tau <sup>2</sup> = Fest for overall effect: .				9 = 0.05	); I² = 52%	6	0.01 0.1 1 10 1 Favours OPCAB Favours ONCAB
o) Acute R	enal	Fail	ure a	OR		Odds Ratio	Odds Ratio
Study or Subaroup	logIO	dds Ra	tiol	SE W	oight P	V. Random, 95% Cl	IV. Random, 95% CI
Mack 2015	10910	1000 Barrier (* 1995) 1995 - State (* 1995)	169 0.17	1993 Barrier 1998	5.2%	0.78 [0.56, 1.09]	
Puskas 2007					4.8%	그것은 그렇게 가슴도 가는 것이야 하셨다.	-
Puskas 2007		-0.44	<b>1</b> 03 U.	126 6	4.0%	0.64 [0.50, 0.82]	
Total (95% CI)				10	0.0%	0.69 [0.56, 0.84]	•
i succi lo s in any							
	= 0.00; Ch	ni² = 0.8	88, df = 1	(P = 0.	35);   <sup>2</sup> = (	)%	
Heterogeneity: Tau <sup>2</sup>			영상 영상 전에 가 있다.	(P = 0.	35); I² = (	0% <u> </u>	CONT. /A OT /A/
Heterogeneity: Tau <sup>2</sup> Test for overall effect			영상 영상 전에 가 있다.	(P = 0.	35);  ² = (	0.01	0.1 1 10 10 Favours OPCAB Favours ONCAB
Heterogeneity: Tau <sup>2</sup> Test for overall effect	t: Z = 3.71	(P = 0	.0002)			)% 0.01	
Heterogeneity: Tau <sup>2</sup>	t: z = 3.71 eplace	eme	nt th	era		0.01	Favours OPCAB Favours ONCAB
Heterogeneity: Tau <sup>2</sup> Test for overall effect	t: z = 3.71 eplace орси	(Р=0 eme	ent th	era	ру	0.01 Odds Ratio	Favours OPCAB Favours ONCAB Odds Ratio
Heterogeneity: Tau <sup>2</sup> Test for overall effect C) Renal re Study or Subgroup	t: Z = 3.71 Place OPC/ Events	(P = 0 Eme	ont th	era B Total	py <sub>Weight</sub>	0.01 Odds Ratio <u>M-H, Random, 95% Cl</u>	Favours OPCAB Favours ONCAB
Heterogeneity: Tau <sup>2</sup> Test for overall effect C) Renal re Study or Subgroup Bucerius 2005	t: Z = 3.71 eplace opc/ <u>Events</u> 1	(P = 0 EME AB Total 152	ont th onc <u>Events</u> 97	B Total 2030	<b>Dy</b> <u>Weight</u> 7.9%	0.01 Odds Ratio <u>M-H, Random, 95% Cl</u> 0.13 [0.02, 0.95]	Favours OPCAB Favours ONCAB Odds Ratio
Heterogeneity: Tau <sup>2</sup> Fest for overall effect C) Renal re Study or Subgroup Bucerius 2005 Puskas 2007	t: Z = 3.71 Events 1 46	(P = 0 <b>E</b> <b>E</b> <b>E</b> <b>E</b> <b>E</b> <b>E</b> <b>E</b> <b>E</b>	0002) ent th ONCA <u>Events</u> 97 134	<b>era</b> B <u>Total</u> 2030 6978	<b>Weight</b> 7.9% 67.8%	0.01 Odds Ratio <u>M-H, Random, 95% Cl</u> 0.13 [0.02, 0.95] 0.49 [0.35, 0.69]	Favours OPCAB Favours ONCAB Odds Ratio
Heterogeneity: Tau <sup>2</sup> Test for overall effect C) Renal re Study or Subgroup Bucerius 2005 Puskas 2007	t: Z = 3.71 eplace opc/ <u>Events</u> 1	(P = 0 EME AB Total 152	ont th onc <u>Events</u> 97	B Total 2030	<b>Dy</b> <u>Weight</u> 7.9%	0.01 Odds Ratio <u>M-H, Random, 95% Cl</u> 0.13 [0.02, 0.95]	Favours OPCAB Favours ONCAB
Heterogeneity: Tau <sup>2</sup> Test for overall effect	t: Z = 3.71 Events 1 46	(P = 0 <b>E</b> <b>E</b> <b>E</b> <b>E</b> <b>E</b> <b>E</b> <b>E</b> <b>E</b>	0002) ent th ONCA <u>Events</u> 97 134	<b>Era</b> Total 2030 6978 401	<b>Weight</b> 7.9% 67.8%	0.01 Odds Ratio <u>M-H, Random, 95% Cl</u> 0.13 [0.02, 0.95] 0.49 [0.35, 0.69]	Favours OPCAB Favours ONCAB Odds Ratio
Heterogeneity: Tau <sup>2</sup> Test for overall effect <b>c) Renal re</b> <u>Study or Subgroup</u> Bucerius 2005 Puskas 2007 Rieß 2017	t: Z = 3.71 Events 1 46	(P = 0 <b>E</b> <b>E</b> <b>E</b> <b>Total</b> 152 4807 259	0002) ent th ONCA <u>Events</u> 97 134	<b>Era</b> Total 2030 6978 401	<b>Weight</b> 7.9% 67.8% 24.3%	0.01 Odds Ratio <u>M-H, Random, 95% Cl</u> 0.13 [0.02, 0.95] 0.49 [0.35, 0.69] 0.84 [0.31, 2.30]	Favours OPCAB Favours ONCAB

Heterogeneity: Tau<sup>2</sup> = 0.10; Chi<sup>2</sup> = 2.86, df = 2 (P = 0.24); I<sup>2</sup> = 30% Test for overall effect: Z = 2.29 (P = 0.02)

Supplementary Fig. 2 - Forest plots demonstrating off-pump coronary artery bypass grafting (OPCAB) vs. on-pump coronary artery bypass grafting (ONCAB) incidence of (a) acute renal failure, (b) acute renal failure with cardiovascular risk factor adjustment, (c) renal replacement therapy. aOR=adjusted odds ratio; Chi=Chi-squared; CI=confidence interval; IV=inverse variance; df=degree of freedom; M-H=Mantel-*Haenszel;* SE=standard error; Tau=Tau-squared

### (a) Deep sternal wound infection

	OPCAB Events Total		ONCAB			Odds Ratio	Odds Ratio			
Study or Subgroup			Events	Total	Weight	M-H. Random, 95% C	5	M-H, Rand	om, 95% Cl	
Bucerius 2005	1	152	38	2030	5.0%	0.35 [0.05, 2.55]		-		
Eifert 2010	4	252	7	481	13.0%	1.09 [0.32, 3.77]		8 <u></u>	-	
Mack 2015	8	3688	16	3688	27.6%	0.50 [0.21, 1.17]			t	
Puskas 2007	13	4807	31	6978	47.3%	0.61 [0.32, 1.16]			t	
Rieß 2017	1	259	7	401	4.5%	0.22 [0.03, 1.78]	7			
Sa 2010	1	549	1	392	2.6%	0.71 [0.04, 11.44]		-		
Total (95% CI)		9707		13970	100.0%	0.58 [0.37, 0.90]		+		
Total events	28		100							
Heterogeneity: Tau <sup>2</sup> =	0.00; Chi <sup>2</sup>	2 = 2.28	, df = 5 (F	P = 0.81)	); l² = 0%		0.04	0.1	1 10	400
Test for overall effect:	Z = 2.40 (	P = 0.0	2)				0.01 Fav	0.1 ours lexperimentall	1 10 Favours [control]	100


## (b) AF

	OPC	AB	ONCAB			Odds Ratio	Odds	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight I	M-H. Random, 95% C	M-H, Rando	om, 95% Cl	
Eifert 2010	88	252	158	481	16.3%	1.10 [0.80, 1.51]	-	-	
Maganti 2007	28	148	21	148	8.6%	1.41 [0.76, 2.62]	1		
Petro 2000	79	304	473	1527	17.8%	0.78 [0.59, 1.03]			
Puskas 2007	870	4807	1377	6978	23.5%	0.90 [0.82, 0.99]			
Rieß 2017	87	259	144	401	16.1%	0.90 [0.65, 1.25]	-	-	
Sa 2010	125	549	147	392	17.6%	0.49 [0.37, 0.65]	-		
Total (95% CI)		6319		9927	100.0%	0.85 [0.68, 1.06]	•		
Total events	1277		2320						
Heterogeneity: Tau <sup>2</sup> =	0.05; Chi <sup>2</sup>	2 = 20.7	7, df = 5 i	(P = 0.0)	0009); l <sup>2</sup> = 78	3%		10	100
Test for overall effect:	Z = 1.44 (	P = 0.1	5)				0.01 0.1 1 Favours [experimental]	10 [control]	100


## (c) Lower cardiac output

	OPC/	٨B	ONC	AB		Odds Ratio		Odds Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H. Random. 95% C	8	M-H	. Random. 9	5% CI	
Bucerius 2005	6	152	140	2030	31.1%	0.55 [0.24, 1.28]		2			
Maganti 2007	6	148	3	148	13.0%	2.04 [0.50, 8.32]			-		
Sa 2010	33	549	25	392	55.9%	0.94 [0.55, 1.61]					
Total (95% CI)		849		2570	100.0%	0.88 [0.52, 1.51]			•		
Total events	45		168								
Heterogeneity: Tau <sup>2</sup> =	0.06; Chi <sup>2</sup>	= 2.62	, df = 2 (F	P = 0.27	7); I <sup>2</sup> = 24%	6	0.04		-	10	400
Test for overall effect: Z = 0.46 (P = 0.65)							0.01 Favou	0.1 Irs (experin	nental] Favo	10 urs [control]	100


**Supplementary Fig. 3** - Forest plots demonstrating off-pump coronary artery bypass grafting (OPCAB) vs. on-pump coronary artery bypass grafting (ONCAB) incidence of (a) deep sternal wound infection, (b) atrial fibrillation (AF), (c) postoperative lower cardiac output. Chi=Chi-squared; Cl=confidence interval; df=degree of freedom; M-H=Mantel-Haenszel; Tau=Tau-squared




**Supplementary Fig. 4** - Funnel plot of off-pump coronary artery bypass grafting vs. on-pump coronary artery bypass grafting for (a) in-hospital mortality, (b) in-hospital mortality with cardiovascular risk factor adjustment, (c) in-hospital mortality of propensity score matching (PSM) studies, (d) 30-day mortality. aOR=adjusted odds ratio; OR=odds ratio; SE=standard error




**Supplementary Fig. 6** - Funnel plot of off-pump coronary artery bypass grafting vs. on-pump coronary artery bypass grafting for (a) blood cell transfusion, (b) re-exploration for bleeding, (c) re-exploration for bleeding of propensity score matching (PSM) studies. OR=odds ratio; SE=standard error



**Supplementary Fig. 5** - Funnel plot of off-pump coronary artery bypass grafting vs. on-pump coronary artery bypass grafting for (a) postoperative stroke incidence, (b) postoperative stroke incidence with cardiovascular risk factor adjustment, (c) postoperative stroke incidence of propensity score matching (PSM) studies, (d) postoperative myocardial infarction (MI) incidence. aOR=adjusted odds ratio; OR=odds ratio; SE=standard error



**Supplementary Fig. 7** - Funnel plot of off-pump coronary artery bypass grafting vs. on-pump coronary artery bypass grafting for (a) acute renal failure, (b) acute renal failure with cardiovascular risk factor adjustment, (c) renal replacement therapy. aOR=adjusted odds ratio; OR=odds ratio; SE=standard error



**Supplementary Fig. 8** - Funnel plot of off-pump coronary artery bypass grafting vs. on-pump coronary artery bypass grafting for (a) atrial fibrillation (AF), (b) deep sternal wound infection, (c) postoperative lower cardiac output. OR=odds ratio; SE=standard error

#### Limitations

Our study has the following shortcomings: 1) we had not retrieved random control studies, so the studies we included were all retrospective case-control observational studies that might attenuate our research's strength; 2) our study did not further explore the effect of sex difference on long-term prognosis after CABG due to the lack of relevant literature.

#### CONCLUSION

Compared to the American Heart Association CABG guideline, the incidence of adverse events in female patients who underwent OPCAB was lower or not significant, but not higher, than in those in the ONCAB group. Our findings should nevertheless be treated with caution due to the limitations attributed to observational studies. Randomized controlled trials are warranted to further substantiate our conclusion in the future.

**Financial support:** This work was supported by Guangzhou City Science and Technology Program (No. 202102021100) and Guangzhou Traditional Chinese medicine and Integrated Traditional Chinese and Western Medicine science and and technology project (20222A010003) to Dr. Jun Fan.

### No conflict of interest.

Authors' Roles & Responsibilities

- JF Substantial contributions to the conception of the work; and the analysis of data for the work; drafting the work and revising it; final approval of the version to be published
- SLL Substantial contributions to the conception of the work; final approval of the version to be published
- YCP Substantial contributions to the design of the work; final approval of the version to be published
- TYW Substantial contributions to the acquisition of data for the work; final approval of the version to be published
- YC Substantial contributions to the conception of the work; and the acquisition of data for the work; final approval of the version to be published
- WJL Substantial contributions to the conception of the work; drafting the work; final approval of the version to be published

#### REFERENCES

- Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2016;68(10):1082-115. doi:10.1016/j.jacc.2016.03.513.
- Wijeysundera HC, Machado M, Farahati F, Wang X, Witteman W, van der Velde G, et al. Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994-2005. JAMA. 2010;303(18):1841-7. doi:10.1001/jama.2010.580.
- Arnold SV, Bhatt DL, Barsness GW, Beatty AL, Deedwania PC, Inzucchi SE, et al. Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American heart association. Circulation. 2020;141(19):e779-e806. doi:10.1161/CIR.000000000000766.
- 4. Mancia G. Should blood pressure reduction be aggressive in patients with hypertension and coronary artery disease? Lancet. 2016;388(10056):2061-2. doi:10.1016/S0140-6736(16)31398-8.
- Goldfine AB, Phua EJ, Abrahamson MJ. Glycemic management in patients with coronary artery disease and prediabetes or type 2 diabetes mellitus. Circulation. 2014;129(24):2567-73. doi:10.1161/ CIRCULATIONAHA.113.006634.
- Linsel-Nitschke P, Samani NJ, Schunkert H. Sorting out cholesterol and coronary artery disease. N Engl J Med. 2010;363(25):2462-3. doi:10.1056/NEJMcibr1010765.
- Opie LH, Commerford PJ, Gersh BJ. Controversies in stable coronary artery disease. Lancet. 2006;367(9504):69-78. doi:10.1016/S0140-6736(06)67927-0.
- Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery. A report of the American college of cardiology foundation/ American heart association task force on practice guidelines. Developed in collaboration with the American association for thoracic surgery, society of cardiovascular anesthesiologists, and society of thoracic surgeons. J Am Coll Cardiol. 2011;58(24):e123-210. doi:10.1016/j.jacc.2011.08.009.
- Kim C, Redberg RF, Pavlic T, Eagle KA. A systematic review of gender differences in mortality after coronary artery bypass graft surgery and percutaneous coronary interventions. Clin Cardiol. 2007;30(10):491-5. doi:10.1002/clc.20000.

- Lamy A, Devereaux PJ, Prabhakaran D, Taggart DP, Hu S, Paolasso E, et al. Off-pump or on-pump coronary-artery bypass grafting at 30 days. N Engl J Med. 2012;366(16):1489-97. doi:10.1056/ NEJMoa1200388.
- 11. Shroyer AL, Grover FL, Hattler B, Collins JF, McDonald GO, Kozora E, et al. On-pump versus off-pump coronary-artery bypass surgery. N Engl J Med. 2009;361(19):1827-37. doi:10.1056/NEJMoa0902905.
- Attaran S, Harling L, Ashrafian H, Moscarelli M, Casula R, Anderson J, et al. Off-pump versus on-pump revascularization in females: a meta-analysis of observational studies. Perfusion. 2014;29(5):385-96. doi:10.1177/0267659114525985.
- 13. Mack MJ, Brown P, Houser F, Katz M, Kugelmass A, Simon A, et al. On-pump versus off-pump coronary artery bypass surgery in a matched sample of women: a comparison of outcomes. Circulation. 2004;110(11 Suppl 1):II1-6. doi:10.1161/01. CIR.0000138198.62961.41.
- 14. Ter Woorst JF, Hoff AHT, Haanschoten MC, Houterman S, van Straten AHM, Soliman-Hamad MA. Do women benefit more than men from off-pump coronary artery bypass grafting? Neth Heart J. 2019;27(12):629-35. doi:10.1007/s12471-019-01333-9.
- 15 Petro KR, Dullum MK, Garcia JM, Pfister AJ, Qazi AG, Boyce SW, et al. Minimally invasive coronary revascularization in women: a safe approach for a high-risk group. Heart Surg Forum. 2000;3(1):41-6.
- Puskas JD, Edwards FH, Pappas PA, O'Brien S, Peterson ED, Kilgo P, et al. Off-pump techniques benefit men and women and narrow the disparity in mortality after coronary bypass grafting. Ann Thorac Surg. 2007;84(5):1447-54; discussion 1454-6. doi:10.1016/j. athoracsur.2007.06.104.
- 17. Capdeville M, Chamogeogarkis T, Lee JH. Effect of gender on outcomes of beating heart operations. Ann Thorac Surg. 2001;72(3):S1022-5. doi:10.1016/s0003-4975(01)02954-x.
- Patel S, Smith JM, Engel AM. Gender differences in outcomes after off-pump coronary artery bypass graft surgery. Am Surg. 2006;72(4):310-3.
- Rieß FC, Behrendt CA, Amin W, Heller S, Hansen L, Winkel S, Stripling J, Rieß HC. Complete arterial revascularization using bilateral internal mammary artery in T-graft technique for multivessel coronary artery disease in on- or off-pump approach: does gender lose its historical impact on clinical outcome? Eur J Cardiothorac Surg. 2017;52(5):917-23. doi:10.1093/ejcts/ezx287.
- 20. Eifert S, Kilian E, Beiras-Fernandez A, Juchem G, Reichart B, Lamm P. Early and mid term mortality after coronary artery bypass grafting in women depends on the surgical protocol: retrospective analysis of 3441 on- and off-pump coronary artery bypass grafting procedures. J Cardiothorac Surg. 2010;5:90. doi:10.1186/1749-8090-5-90.

- 21. Bucerius J, Gummert JF, Walther T, Borger MA, Doll N, Falk V, et al. Impact of off-pump coronary bypass grafting on the prevalence of adverse perioperative outcome in women undergoing coronary artery bypass grafting surgery. Ann Thorac Surg. 2005;79(3):807-12; discussion 812-3. doi:10.1016/j.athoracsur.2004.06.013.
- 22. Sá MP, Lima LP, Rueda FG, Escobar RR, Cavalcanti PE, Thé EC, et al. Comparative study between on-pump and off-pump coronary artery bypass graft in women. Rev Bras Cir Cardiovasc. 2010;25(2):238-44. doi:10.1590/s0102-76382010000200018.
- 23. Woś S, Bachowski R, Jasiński M, et al. Coronary artery bypass grafting in women without the use of cardiopulmonary bypass. A comparison with patients operated on in a standard faxion. Kardiol Polska. 2001;54(Suppl. 1):156-160.
- Czech B, Kucewicz-Czech E, Pacholewicz J, Wojarski J, Puzio J, Przybylski R, et al. Early results of coronary artery bypass graft surgery in women. Kardiol Pol. 2007;65(6):627-33; discussion 634.
- 25. Perek B, Jemielity M, Dyszkiewicz W. Why are the results of coronary artery bypass grafting in women worse? Asian Cardiovasc Thorac Ann. 2003;11(4):293-8. doi:10.1177/021849230301100405.
- Emmert MY, Salzberg SP, Seifert B, Schurr UP, Odavic D, Reuthebuch O, et al. Despite modern off-pump coronary artery bypass grafting women fare worse than men. Interact Cardiovasc Thorac Surg. 2010;10(5):737-41. doi:10.1510/icvts.2009.220277.
- 27. Maganti M, Rao V, Cusimano RJ. Sex differences in resource use after on-pump and off-pump coronary artery bypass surgery: a propensity score-matched cohort. Can J Cardiol. 2009;25(5):e151-6. doi:10.1016/s0828-282x(09)70498-2.
- Cartier R, Bouchot O, El-Hamamsy I. Influence of sex and age on long-term survival in systematic off-pump coronary artery bypass surgery. Eur J Cardiothorac Surg. 2008;34(4):826-32. doi:10.1016/j. ejcts.2008.07.024.
- Risum O, Abdelnoor M, Nitter-Hauge S, Levorstad K, Svennevig JL. Coronary artery bypass surgery in women and in men; early and long-term results. A study of the Norwegian population adjusted by age and sex. Eur J Cardiothorac Surg. 1997;11(3):539-46. doi:10.1016/s1010-7940(96)01107-4.
- Brandrup-Wognsen G, Berggren H, Hartford M, Hjalmarson A, Karlsson T, Herlitz J. Female sex is associated with increased mortality and morbidity early, but not late, after coronary artery bypass grafting. Eur Heart J. 1996;17(9):1426-31. doi:10.1093/ oxfordjournals.eurheartj.a015078.
- Gaudino M, Bakaeen F, Davierwala P, Di Franco A, Fremes SE, Patel N, et al. New strategies for surgical myocardial revascularization. Circulation. 2018;138(19):2160-8. doi:10.1161/ CIRCULATIONAHA.118.035956.



This is an open-access article distributed under the terms of the Creative Commons Attribution License.